C3 and thrombotic thrombocytopenic purpura: Ravulizumab was started on day 2 after thrombotic thrombocytopenic purpura and Shiga toxin-associated HUS were excluded, and aHUS was clinically suspected on the basis of isolated C3 hypocomplementemia.